(CNBC) – Sanofi launched an inhalable insulin in the United States on Tuesday in a potential boost for its flagging diabetes drug sales and for patient quality of life. Developed by Mannkind, Afrezza will be the only inhalable insulin on the U.S. market, where Sanofi competes with Eli Lilly and Novo Nordisk for sales of traditional injectable insulin. Inhalation promises to be […]
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.
